Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 6,751	$ 4,612
Short-term investments	71,440	46,490
Prepaid expenses and other current assets	3,318	5,027
Total current assets	81,509	56,129
Operating lease asset, net	471	365
In-process research and development	32,386	32,386
Other assets	210	186
Total assets	114,576	89,066
Current liabilities:
Accounts payable	5,860	967
Current operating lease liabilities	186	383
Accrued expenses and other liabilities	6,443	2,545
Total current liabilities	12,489	3,895
Deferred tax liabilities	1,752	1,752
Non-current operating lease liabilities	315
Warrant liabilities	23,962	76,211
Total liabilities	38,518	81,858
Commitments and contingencies (Note 7)
Stockholders' equity:
Common stock, $0.001 par value, 200,000,000 shares authorized at September 30, 2024 and December 31, 2023; 41,183,102 and 24,213,130 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively	41	24
Additional paid-in capital	386,884	326,586
Accumulated other comprehensive loss	102
Accumulated deficit	(310,969)	(319,402)
Total stockholders’ equity	76,058	7,208
Total liabilities and stockholders' equity	114,576	89,066
Series X1 Non-voting Convertible Preferred Stock [Member]
Stockholders' equity:
Preferred stock, value
Series X Non-voting Convertible Preferred Stock [Member]
Stockholders' equity:
Preferred stock, value

In-process research and development.

No definition available.

Name:	eldn_InProcessResearchAndDevelopment
Namespace Prefix:	eldn_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).